These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 9438229)

  • 1. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A; Bosc M; Polin V
    J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A; Bosc M; Polin V
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J
    J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
    Bosc M; Dubini A; Polin V
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S57-70; discussion S71-3. PubMed ID: 9169311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
    Venditti LN; Arcelus A; Birnbaum H; Greenberg P; Barr CE; Rowland C; Williamson T
    Int Clin Psychopharmacol; 2000 Sep; 15(5):279-89. PubMed ID: 10993130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reboxetine: additional benefits to the depressed patient.
    Montgomery SA
    J Psychopharmacol; 1997; 11(4 Suppl):S9-15. PubMed ID: 9438228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of social functioning in depression.
    Bosc M
    Compr Psychiatry; 2000; 41(1):63-9. PubMed ID: 10646621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E; Demir EY; Cosar B
    Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
    Keller M
    Gen Hosp Psychiatry; 2001; 23(1):15-9. PubMed ID: 11226552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reboxetine: the first selective noradrenaline re-uptake inhibitor.
    Kasper S; el Giamal N; Hilger E
    Expert Opin Pharmacother; 2000 May; 1(4):771-82. PubMed ID: 11249515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J; Möller HJ; Burrows GD; Montenegro RM
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
    Nelson JC; Portera L; Leon AC
    Biol Psychiatry; 2005 Jun; 57(12):1535-42. PubMed ID: 15953490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC; Portera L; Leon AC
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study.
    Nelson JC; Mazure CM; Jatlow PI; Bowers MB; Price LH
    Biol Psychiatry; 2004 Feb; 55(3):296-300. PubMed ID: 14744472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of reboxetine in major depression.
    Schatzberg AF
    J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
    Healy D
    Acta Psychiatr Scand Suppl; 2000; 402():45-51. PubMed ID: 10901159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting response: noradrenaline reuptake inhibition.
    Montgomery SA
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S21-6. PubMed ID: 10468325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between noradrenergic and serotonergic medications using the social adjustment scale: is drive enhancement necessary for recovery of social functioning?
    Luty SE; Joyce PR; Mulder RT
    J Psychopharmacol; 2001 Dec; 15(4):257-64. PubMed ID: 11769819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
    Aragona M; Bancheri L; Perinelli D; Tarsitani L; Pizzimenti A; Conte A; Inghilleri M
    Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.